PCIF1 and renal cell carcinoma: Lately, multiple investigations have shed light on a connection between TKI resistance and a metabolic shift marked by enhanced OXPHOS.[48, 49] Given that PCIF1 enhances OXPHOS in RCC, we are intrigued by the possibility that suppressing PCIF1 could sensitize RCC cells to sunitinib treatment.